<DOC>
	<DOCNO>NCT00518206</DOCNO>
	<brief_summary>The purpose clinical trial cohort test effect add low dose cyclophosphamide treatment NY-ESO-1 ISCOM® vaccine , patient measurable advanced malignant melanoma ( unresectable stage III metastatic melanoma ) .</brief_summary>
	<brief_title>Study NY-ESO-1 ISCOMATRIX® Patients With Measurable Stage III IV Melanoma</brief_title>
	<detailed_description>This clinical trial cohort test combination NY-ESO-1 ISCOMATRIX® vaccine give low dose cyclophosphamide patient advance melanoma . NY-ESO-1 protein immune target find many cancer include melanoma . ISCOMATRIX® adjuvant enhances immune response . Low dose cyclophosphamide show suppress population lymphocytes call `` regulatory T cell '' . Regulatory T cell interfere immune response patient cancer . The rationale treat new cohort patient study use small dose cyclophosphamide suppress regulatory T cell thus try increase patient responses NY-ESO-1 ISCOMATRIX® vaccine . Eligible patient receive three intramuscular injection NY-ESO-1 ISCOM® vaccine approximately four-week interval ( week 1 , week 5 , week 9 ) . Low dose cyclophosphamide administer intravenous infusion one day prior NY-ESO-1 ISCOM® vaccine . Tumor evaluation ( CT scan physical evaluation ) , safety evaluation ( blood test medical review ) immunological testing ( special DTH skin test blood immunology test ) perform , end 11 week treatment cycle . Treatment may continue cycle unless reason remove patient study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Stage IV ( metastatic ) unresectable stage III malignant melanoma . Tumor expression NYESO1 antigen immunohistochemistry . Measurable disease ( RECIST criterion ) . No effective therapy available appropriate . Expected survival least 4 month . Performance status ( Karnofsky ) 70 % great . Vital laboratory parameter within normal range , protocol specify range . Age 18 year old . Able give write informed consent . Other serious significant illness . Other malignancy within last 3 year , except treat melanoma nonmelanoma skin cancer cervical cancer situ . Known immunodeficiency Known HIV positivity Using systemic immunosuppressive drug . ( Exceptions : Specific COX2 inhibitor ; low dose aspirin acute cardiovascular event prevention ; topical/inhaled steroid ) Chemotherapy , immunotherapy radiotherapy within last four week . Participation prior clinical trial involve investigational agent within last 4 week . Not available immunological clinical followup assessment . Pregnancy breastfeed . Refusal inability use effective mean contraception woman childbearing potential . Mental impairment may compromise ability give informed consent comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Phase II</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>NY-ESO-1 protein , human</keyword>
	<keyword>ISCOMATRIX , immunological adjuvant</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>T-Cells , Regulatory</keyword>
</DOC>